Troubled Amgen pays CEO $13.2M in compensation
With its shares plunging and regulators threatening its blockbuster anemia franchise, Amgen CEO Kevin Sharer (photo) nevertheless garnered $13.2 million in compensation last year, according to the AP. Sharer's fortunes waned by a hefty 29 percent, dropping from $18.6 million taken in the halcyon days of 2006. Sharer took home $1.5 million in pay last year (up), $1.5 million in bonuses (down) and stock and options valued at $9.3 million when they were offered (also down). The perks of the job may have softened the blow, though. Sharer's use of a company plane, Amgen car and driver and tax and financial planning services were worth a collective $900,000. Amgen shareholders did a little worse than the CEO. Company shares plunged 35 percent last year.
- read the AFX story
Related Articles:
Amgen--Big Biotech's Stock Report. Report
Amgen CEO touts blockbuster potential of D-mab. Report
Amgen discusses the future with analysts. Report
Amgen in crisis? Not us, says CEO Sharer. Report
Comments (2) | Post a comment
Comments
By Anonymous | Posted 5:22pm | April 21, 2008
Sharer doesn't deserve a dime. He's the reason why the company is being driven into the ground. Where's the BOD? Oh i forgot their in bed with him too. Isn't that a conflict of interest.
By Anonymous | Posted 1:32pm | April 24, 2008
Yes it is a old-boys company. Amgen will go down the drain in few years, mean time these folks will suck the life out of the company. Why is not the company selling its "Aviation department" as part of the operational excellence?
Post new comment
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
